Sustained-release bupropion for smoking cessation in African Americans: A randomized controlled trial

TitleSustained-release bupropion for smoking cessation in African Americans: A randomized controlled trial
Publication TypeJournal Article
Year of Publication2002
AuthorsAhluwalia, JS, Harris, KJ, Catley, D, Okuyemi, KS, Mayo, MS
JournalJournal of the American Medical Association
Date PublishedJul 24-31
Publication Languageeng
ISBN Number0098-7484 (Print)0098-7484 (Linking)
Accession Number12132977
Keywords*African Americans, Adult, Bupropion/*therapeutic use, Delayed-Action Preparations, Dopamine Uptake Inhibitors/*therapeutic use, Double-Blind Method, Female, Humans, Male, Middle Aged, Smoking Cessation/ethnology/*methods, Tobacco Use Disorder/*drug therapy/ethnology

CONTEXT: African Americans disproportionately experience greater smoking attributable morbidity and mortality. Few clinical trials for smoking cessation in African Americans have been conducted, despite a different profile of both smoking and quitting patterns. OBJECTIVE: To compare a sustained-release form of bupropion hydrochloride (bupropion SR) with placebo for smoking cessation among African Americans. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted from February 11, 1999, to December 8, 2000, of 600 African American adults treated at a community-based health care center. Volunteers, who smoked 10 or more cigarettes per day were recruited by targeted media and health care professionals. INTERVENTION: Participants were randomly assigned to receive 150 mg of bupropion SR (n = 300) or placebo (n = 300) twice daily for 7 weeks. Brief motivational counseling was provided in-person at baseline, quit day, weeks 1 and 3, end of treatment (week 6), and by telephone at day 3 and weeks 5 and 7. MAIN OUTCOME MEASURES: Biochemically confirmed 7-day point prevalence abstinence at weeks 6 and 26 following quit day. RESULTS: Using intention-to-treat procedures, confirmed abstinence rates at the end of 7 weeks of treatment were 36.0% in the bupropion SR group and 19.0% in the placebo group (17.0 percentage point difference; 95% confidence interval, 9.7-24.4; P<.001). At 26 weeks the quit rates were 21.0% in the treatment and 13.7% in the placebo groups (7.3 percentage point difference; 95% confidence interval, 1.0-13.7; P =.02). Those taking bupropion SR experienced a greater mean reduction in depression symptoms at week 6 (2.96 [9.45] vs 1.13 [8.84]) than those taking placebo, and after controlling for continuous abstinence, those taking bupropion SR also gained less weight than those taking placebo. CONCLUSIONS: Bupropion SR was effective for smoking cessation among African Americans and may be useful in reducing the health disparities associated with smoking.

Go to top